Endpoints for Clinical Trials Testing Treatment of Acute Graft-versus-Host Disease: A Joint Statement

Paul J. Martin; Carlos R. Bachier; Hans Georg Klingemann; Philip L. McCarthy; Paul Szabolcs; Joseph P. Uberti; Michael W. Schuster; Daniel J Weisdorf; Nelson J. Chao; Partow Kebriaei; Elizabeth J. Shpall; Margaret L MacMillan; Robert J. Soiffer

doi:10.1016/j.bbmt.2009.03.012

Endpoints for Clinical Trials Testing Treatment of Acute Graft-versus-Host Disease: A Joint Statement

Paul J. Martin, Carlos R. Bachier, Hans Georg Klingemann, Philip L. McCarthy, Paul Szabolcs, Joseph P. Uberti, Michael W. Schuster, Daniel J Weisdorf, Nelson J. Chao, Partow Kebriaei, Elizabeth J. Shpall, Margaret L MacMillan, Robert J. Soiffer

Research output: Contribution to journal › Article › peer-review

61 Scopus citations

Abstract

Currently, no agents are approved by the United States Food and Drug Administration (FDA) for either prevention or treatment of acute graft-versus-host disease (aGVHD). Formal precedents establishing a comparative basis for assessing the efficacy and safety of new investigational agents are still lacking. As a step toward addressing this problem, a panel of experts met on 2 occasions to reach consensus on recommendations for terminology describing a clinically meaningful primary endpoint in studies assessing treatment for aGVHD. The panel recommended terminology for "very good partial response" (VGPR) that includes both diagnostic and functional criteria. The central hypothesis leading to this proposal is that the potential harm of giving more treatment than needed to produce or maintain complete response exceeds the harm of slight undertreatment that may be associated with less than complete response. VGPR clearly cannot be used as the sole outcome measure in GVHD treatment trials, and must be considered in the context of survival and safety. The proposed use of VGPR as the primary endpoint in GVHD treatment trials will remain provisional until its use has been validated through experience.

Original language	English (US)
Pages (from-to)	777-784
Number of pages	8
Journal	Biology of Blood and Marrow Transplantation
Volume	15
Issue number	7
DOIs	https://doi.org/10.1016/j.bbmt.2009.03.012
State	Published - Jul 2009

Bibliographical note

Funding Information:
P.J.M., C.R.B., and M.W.S., research support from Osiris Therapeutics; H.-G.K, independent safety monitor for a clinical trial sponsored by Osiris Therapeutics; D.W., research support from Amgen, Hospira, Easai, Roche, Genzyme, and honoraria for advisory board participation from Genzyme, Dor, Hospira, and Osiris; R.J.S., P.L.M., P.S., J.P.U., N.J.C., P.W., E.J.S., and M.L.M., no additional relevant financial disclosures.

Funding Information:
Financial disclosure: The consensus meetings were held on September 11, 2007, and on May 23, 2008, and were sponsored by Osiris Therapeutics, Inc., Columbia, MD. Osiris provided honoraria to the participants (except P.J.M.), but did not contribute to the meeting output or to the content of this manuscript. Effort by P.J.M. was supported by grant CA18029 from the National Institutes of Health, Department of Health and Human Services.

Keywords

Acute graft-versus-host disease
Clinical trials
Endpoints
Guidelines

Access

10.1016/j.bbmt.2009.03.012

OpenUrl availability

Full text

Cite this

Martin, P. J., Bachier, C. R., Klingemann, H. G., McCarthy, P. L., Szabolcs, P., Uberti, J. P., Schuster, M. W., Weisdorf, D. J., Chao, N. J., Kebriaei, P., Shpall, E. J., MacMillan, M. L., & Soiffer, R. J. (2009). Endpoints for Clinical Trials Testing Treatment of Acute Graft-versus-Host Disease: A Joint Statement. Biology of Blood and Marrow Transplantation, 15(7), 777-784. https://doi.org/10.1016/j.bbmt.2009.03.012

Martin, PJ, Bachier, CR, Klingemann, HG, McCarthy, PL, Szabolcs, P, Uberti, JP, Schuster, MW, Weisdorf, DJ, Chao, NJ, Kebriaei, P, Shpall, EJ, MacMillan, ML & Soiffer, RJ 2009, 'Endpoints for Clinical Trials Testing Treatment of Acute Graft-versus-Host Disease: A Joint Statement', Biology of Blood and Marrow Transplantation, vol. 15, no. 7, pp. 777-784. https://doi.org/10.1016/j.bbmt.2009.03.012

@article{3f48a68ef5b745e99427a548ffff2730,

title = "Endpoints for Clinical Trials Testing Treatment of Acute Graft-versus-Host Disease: A Joint Statement",

abstract = "Currently, no agents are approved by the United States Food and Drug Administration (FDA) for either prevention or treatment of acute graft-versus-host disease (aGVHD). Formal precedents establishing a comparative basis for assessing the efficacy and safety of new investigational agents are still lacking. As a step toward addressing this problem, a panel of experts met on 2 occasions to reach consensus on recommendations for terminology describing a clinically meaningful primary endpoint in studies assessing treatment for aGVHD. The panel recommended terminology for {"}very good partial response{"} (VGPR) that includes both diagnostic and functional criteria. The central hypothesis leading to this proposal is that the potential harm of giving more treatment than needed to produce or maintain complete response exceeds the harm of slight undertreatment that may be associated with less than complete response. VGPR clearly cannot be used as the sole outcome measure in GVHD treatment trials, and must be considered in the context of survival and safety. The proposed use of VGPR as the primary endpoint in GVHD treatment trials will remain provisional until its use has been validated through experience.",

keywords = "Acute graft-versus-host disease, Clinical trials, Endpoints, Guidelines",

author = "Martin, {Paul J.} and Bachier, {Carlos R.} and Klingemann, {Hans Georg} and McCarthy, {Philip L.} and Paul Szabolcs and Uberti, {Joseph P.} and Schuster, {Michael W.} and Weisdorf, {Daniel J} and Chao, {Nelson J.} and Partow Kebriaei and Shpall, {Elizabeth J.} and MacMillan, {Margaret L} and Soiffer, {Robert J.}",

note = "Funding Information: P.J.M., C.R.B., and M.W.S., research support from Osiris Therapeutics; H.-G.K, independent safety monitor for a clinical trial sponsored by Osiris Therapeutics; D.W., research support from Amgen, Hospira, Easai, Roche, Genzyme, and honoraria for advisory board participation from Genzyme, Dor, Hospira, and Osiris; R.J.S., P.L.M., P.S., J.P.U., N.J.C., P.W., E.J.S., and M.L.M., no additional relevant financial disclosures. Funding Information: Financial disclosure: The consensus meetings were held on September 11, 2007, and on May 23, 2008, and were sponsored by Osiris Therapeutics, Inc., Columbia, MD. Osiris provided honoraria to the participants (except P.J.M.), but did not contribute to the meeting output or to the content of this manuscript. Effort by P.J.M. was supported by grant CA18029 from the National Institutes of Health, Department of Health and Human Services. ",

year = "2009",

month = jul,

doi = "10.1016/j.bbmt.2009.03.012",

language = "English (US)",

volume = "15",

pages = "777--784",

journal = "Biology of Blood and Marrow Transplantation",

issn = "1083-8791",

publisher = "Elsevier Inc.",

number = "7",

}

TY - JOUR

T1 - Endpoints for Clinical Trials Testing Treatment of Acute Graft-versus-Host Disease

T2 - A Joint Statement

AU - Martin, Paul J.

AU - Bachier, Carlos R.

AU - Klingemann, Hans Georg

AU - McCarthy, Philip L.

AU - Szabolcs, Paul

AU - Uberti, Joseph P.

AU - Schuster, Michael W.

AU - Weisdorf, Daniel J

AU - Chao, Nelson J.

AU - Kebriaei, Partow

AU - Shpall, Elizabeth J.

AU - MacMillan, Margaret L

AU - Soiffer, Robert J.

N1 - Funding Information: P.J.M., C.R.B., and M.W.S., research support from Osiris Therapeutics; H.-G.K, independent safety monitor for a clinical trial sponsored by Osiris Therapeutics; D.W., research support from Amgen, Hospira, Easai, Roche, Genzyme, and honoraria for advisory board participation from Genzyme, Dor, Hospira, and Osiris; R.J.S., P.L.M., P.S., J.P.U., N.J.C., P.W., E.J.S., and M.L.M., no additional relevant financial disclosures. Funding Information: Financial disclosure: The consensus meetings were held on September 11, 2007, and on May 23, 2008, and were sponsored by Osiris Therapeutics, Inc., Columbia, MD. Osiris provided honoraria to the participants (except P.J.M.), but did not contribute to the meeting output or to the content of this manuscript. Effort by P.J.M. was supported by grant CA18029 from the National Institutes of Health, Department of Health and Human Services.

PY - 2009/7

Y1 - 2009/7

N2 - Currently, no agents are approved by the United States Food and Drug Administration (FDA) for either prevention or treatment of acute graft-versus-host disease (aGVHD). Formal precedents establishing a comparative basis for assessing the efficacy and safety of new investigational agents are still lacking. As a step toward addressing this problem, a panel of experts met on 2 occasions to reach consensus on recommendations for terminology describing a clinically meaningful primary endpoint in studies assessing treatment for aGVHD. The panel recommended terminology for "very good partial response" (VGPR) that includes both diagnostic and functional criteria. The central hypothesis leading to this proposal is that the potential harm of giving more treatment than needed to produce or maintain complete response exceeds the harm of slight undertreatment that may be associated with less than complete response. VGPR clearly cannot be used as the sole outcome measure in GVHD treatment trials, and must be considered in the context of survival and safety. The proposed use of VGPR as the primary endpoint in GVHD treatment trials will remain provisional until its use has been validated through experience.

AB - Currently, no agents are approved by the United States Food and Drug Administration (FDA) for either prevention or treatment of acute graft-versus-host disease (aGVHD). Formal precedents establishing a comparative basis for assessing the efficacy and safety of new investigational agents are still lacking. As a step toward addressing this problem, a panel of experts met on 2 occasions to reach consensus on recommendations for terminology describing a clinically meaningful primary endpoint in studies assessing treatment for aGVHD. The panel recommended terminology for "very good partial response" (VGPR) that includes both diagnostic and functional criteria. The central hypothesis leading to this proposal is that the potential harm of giving more treatment than needed to produce or maintain complete response exceeds the harm of slight undertreatment that may be associated with less than complete response. VGPR clearly cannot be used as the sole outcome measure in GVHD treatment trials, and must be considered in the context of survival and safety. The proposed use of VGPR as the primary endpoint in GVHD treatment trials will remain provisional until its use has been validated through experience.

KW - Acute graft-versus-host disease

KW - Clinical trials

KW - Endpoints

KW - Guidelines

UR - http://www.scopus.com/inward/record.url?scp=67349104999&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67349104999&partnerID=8YFLogxK

U2 - 10.1016/j.bbmt.2009.03.012

DO - 10.1016/j.bbmt.2009.03.012

M3 - Article

C2 - 19539208

AN - SCOPUS:67349104999

SN - 1083-8791

VL - 15

SP - 777

EP - 784

JO - Biology of Blood and Marrow Transplantation

JF - Biology of Blood and Marrow Transplantation

IS - 7

ER -

Endpoints for Clinical Trials Testing Treatment of Acute Graft-versus-Host Disease: A Joint Statement

Abstract

Bibliographical note

Keywords

Access

OpenUrl availability

Other files and links

Fingerprint

Cite this